Costco Wholesale Corp /New
—- Market cap
- $400.28B
- Debt
- —
- Cash
- −$14.16B
Complete market value, debt and cash evidence is required for enterprise value.
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: COST stock price vs CVS: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at CVS's multiple
Needs CVS P/E.
Implied fair value · at COST's multiple
Price unavailable
Metric by metric
Where each company leads, and how wide the gap is.
Growth edge
Reported gross margin
Operating income + D&A
Lower is better
Not comparable
Lower leverage
Statements
Annual statements in reported currencies, with calculations and source evidence.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Trendline
16 period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
USD market cap plus reported borrowing debt, less cash and equivalents. This EV proxy excludes investments, preferred stock and noncontrolling-interest adjustments.
Complete market value, debt and cash evidence is required for enterprise value.
Complete market value, debt and cash evidence is required for enterprise value.
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
COSTCO WHOLESALE CORP /NEW · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
CVS HEALTH CORPORATION · implied price per share
Bear
$43.35
Base
$58.49
Bull
$78.21
Balance sheet health
Inspect reported liquidity and leverage alongside historical financial-health checks.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
Walmart Inc.
COST vs WMT
TARGET CORP
COST vs TGT
KROGER CO
COST vs KR
DOLLAR GENERAL CORP
COST vs DG
AMAZON COM INC
COST vs AMZN
HOME DEPOT, INC.
COST vs HD
Walgreens Boots Alliance, Inc.
COST vs WBA
UNITEDHEALTH GROUP INC
COST vs UNH
Cigna Group
COST vs CI
HUMANA INC
COST vs HUM
Elevance Health, Inc.
COST vs ELV
Cash excludes investments. EBITDA is an operating-income-plus-D&A proxy. Missing borrowing categories remain unavailable; select a value to inspect its inputs.
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.
If you believe COST can sustain its high ROIC, superior margins, and low leverage while continuing to grow revenue faster than CVS, then owning COST makes sense because the valuation premium is supported by materially better fundamentals and balance sheet quality.
On a P/E basis, COST screens cheaper than CVS-implied upside would suggest at 52.3x versus CVS at 75.3x, while the model-implied price of $1,371.91 implies 44.2% upside from the current $951.67. The valuation gap is complicated by COST’s much higher quality profile, which helps explain why it trades on a premium multiple despite only modest revenue growth outpacing CVS.
Supporting Metrics